Many trials combine chemotherapy, but with EGFR-mutated NSCLC, it will be interesting to see if a combination of ADC with EGFR TKI as studied in HER3-DXd with osimertinib will prove to be more efficacious and not more toxic than ADC monotherapy, and if so, if this combination will be more effective than ADC with chemotherapy (NCT04676477). This evidence concerns the gene EGFR and non-small cell lung carcinoma.